GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (NAS:TXMD) » Definitions » Pretax Margin %

TXMD (TherapeuticsMD) Pretax Margin % : 12.44% (As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is TherapeuticsMD Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. TherapeuticsMD's Pre-Tax Income for the three months ended in Dec. 2024 was $0.08 Mil. TherapeuticsMD's Revenue for the three months ended in Dec. 2024 was $0.67 Mil. Therefore, TherapeuticsMD's pretax margin for the quarter that ended in Dec. 2024 was 12.44%.

The historical rank and industry rank for TherapeuticsMD's Pretax Margin % or its related term are showing as below:

TXMD' s Pretax Margin % Range Over the Past 10 Years
Min: -3082.2   Med: -440.43   Max: 1.54
Current: -133.05


TXMD's Pretax Margin % is ranked worse than
90.78% of 976 companies
in the Drug Manufacturers industry
Industry Median: 5.995 vs TXMD: -133.05

TherapeuticsMD Pretax Margin % Historical Data

The historical data trend for TherapeuticsMD's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Pretax Margin % Chart

TherapeuticsMD Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -282.90 -3,082.20 1.54 -594.62 -133.05

TherapeuticsMD Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -315.54 -258.47 -448.72 -103.66 12.44

Competitive Comparison of TherapeuticsMD's Pretax Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TherapeuticsMD's Pretax Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's Pretax Margin % falls into.


;
;

TherapeuticsMD Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

TherapeuticsMD's Pretax Margin for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-2.343/1.761
=-133.05 %

TherapeuticsMD's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=0.083/0.667
=12.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TherapeuticsMD  (NAS:TXMD) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


TherapeuticsMD Pretax Margin % Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


TherapeuticsMD Business Description

Traded in Other Exchanges
Address
951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
Executives
Collins Cooper C. director 33219 FOREST WEST DRIVE, MAGNOLIA TX 77354
Marlan D Walker officer: General Counsel 951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431
Joseph Ziegler officer: Principal Financial Officer 1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062
Michael C Donegan officer: CAO and VP of Finance 6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Brian Bernick director 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Mark A Glickman officer: Chief Business Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Justin Hunter Roberts director C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Paul Bisaro director
Jules A. Musing director 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
David Efraim Rosen 10 percent owner 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017

TherapeuticsMD Headlines

From GuruFocus

TherapeuticsMD Announces First Quarter 2023 Financial Results

By Business Wire Business Wire 05-15-2023

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

By Business Wire Business Wire 08-01-2022

TherapeuticsMD Announces Expiration of Tender Offer

By Business Wire Business Wire 07-13-2022